Study identifier:9238IL/0004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open Phase II Study to determine if Partial or Complete Responses can be achieved with the Slow Release formulation of a Pure Anti-oestrogen (ICI 182,780) in Post-menopausal Women with Advanced Breast Cancer who have Relapsed on Tamoxifen Therapy
Breast Cancer
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|